What is SANA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.84B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SANA?

P/E (TTM) is n/a and 52-week range is $2.61 to $6.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SANA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SANA?

The company profile lists net income (TTM) near $-212M, EPS (TTM) near $-0.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sana Biotechnology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Seattle, Washington, US, 278.3M shares outstanding, ISIN US7995661045 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Sana Biotechnology Inc

$SANA

Health Care · Biotechnology

IR Run Scenarios

$2.79

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Employees

142

Website

sana.com/

IPO

2021-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)